* Q4 growth partly offset by SMS volumes * Raising EBITA by 7-6% for '26e-'27e * 11-9x EV/EBITA on '...
We lower sales by 4% and cut EBIT by SEK 4-12m in 2026E-28E.
Redeye is optimistic about the new investigator-sponsored phase II trial in respiratory infections, ...
Redeye comments on ExpreS2ion’s announcement of updated Phase I immunogenicity data for its HER2-tar...
Siljansvik announced that its majority-owned subsidiary Dala Vind has received an additional milesto...
Vaisala reports Q4 results on Feb 12. We believe Vaisala’s FY’25 EBITA improved only slightly y/y, w...
Substansvärdet uppgick till 67 kr per aktie och minskade med 2 % jämfört med föregående kvartal, exk...
* 24% organic sales growth in Q4 (ABGSCe +27%) Adj.
Q4 sales was SEK 45m (-6% vs. SEB at SEK 48m) corresponding to 24% y/y growth at constant exchange r...
Vitrolife’s Q4 report came in very close to our projections, reflecting modest underlying growth and...
Ahead of NoHo's Q4 2025 report, due out on 11 February, we lower our estimates slightly to reflect t...
* Strong Q4 on the cards: EBIT SEK 41m (SEK -18m Q4'24) * Slightly lowered Q4 assumptions, but '26e-...
We initiate coverage of Tekova with a BUY rating and a target price (TP) of EUR 1.
Finnair reports Q4 results on Feb 11. FY’25 was challenging due to labor issues, but right now the o...
Leaddesk just announced a small bolt-on acquisition of Fluentic, an AI-powered translation solution.
* Underlying performance indicative of a brighter '26e * '26e-'27e adj.
Redeye observes that Enea's Q4 2025 results delivered an adj.
Redeye updates its estimates and valuation after Indutrade’s Q4 2025 report.
We think Siili’s Q4 will provide a lot of factors to understand whether the market is turning.
* 2025 to end on a soft note * We cut '26e-'27e adj.
